ArticleBioinformatics (Oxford, England)2026
PRISM: Prior-enhanced Inference for Spatial Transcriptomic Cell Type Mapping.
Article in Bioinformatics (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
motivationCell type annotation in spatial transcriptomics (ST) is fundamental for deciphering complex tissue organization and spatially resolved biological processes. Most existing methods perform ST cell type annotation by transferring labels from single-cell RNA-seq (scRNA) data to ST data, but typically rely on weakly constrained representations that neglect structured spatial dependencies and treat marker gene selection as an isolated preprocessing step. This renders them vulnerable to substantial domain gaps as well as platform-specific noise, resulting in unstable predictions and limited biological interpretability.
resultsTo address these issues, we propose Prior-enhanced Inference for Spatial Transcriptomic Cell Type Mapping (PRISM), a novel three-stage framework integrating biological prior construction, pseudo-label generation, and multi-level ST refinement. First, PRISM constructs a cross-domain biological prior to explicitly extract marker genes to enforce positive biological discriminability. Next, it adopts a prior-enhanced self-training strategy, where scRNA-trained ensembles generate reliable pseudo-label candidates for ST data, serving as a robust anchor for cross-domain adaptation. Finally, the framework consolidates high-quality ensemble predictions selected via metric-guided evaluation, encodes spatial information, and optimizes the model under dual-directional biological constraints. Extensive experiments on eleven ST datasets across six platforms, two species, and multiple tissue contexts validate PRISM. Specifically, on the five labeled benchmarks, PRISM shows strong overall performance under both Accuracy and Macro-F1 evaluation across brain and non-brain tissues. Moreover, under fully label-free settings, PRISM achieves the best overall composite rank across all datasets, demonstrating strong robustness to domain shift and platform heterogeneity. AVAILABILITY AND IMPLEMENTATION: PRISM is available at https://github.com/lilab-ai4s/PRISM and https://doi.org/10.5281/zenodo.20529683.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.